ATE501127T1 - Neue cysteinproteasehemmer und ihre therapeutische anwendung - Google Patents

Neue cysteinproteasehemmer und ihre therapeutische anwendung

Info

Publication number
ATE501127T1
ATE501127T1 AT06808884T AT06808884T ATE501127T1 AT E501127 T1 ATE501127 T1 AT E501127T1 AT 06808884 T AT06808884 T AT 06808884T AT 06808884 T AT06808884 T AT 06808884T AT E501127 T1 ATE501127 T1 AT E501127T1
Authority
AT
Austria
Prior art keywords
therapeutic use
new
protease inhibitors
cystein protease
cystein
Prior art date
Application number
AT06808884T
Other languages
English (en)
Inventor
Philippe Guedat
Guillaume Boissy
Catherine Borg-Capra
Frederic Colland
Laurent Daviet
Etienne Formstecher
Xavier Jacq
Jean-Christophe Rain
Remi Delansorne
Stefania Vallese
Matteo Colombo
Original Assignee
Hybrigenics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05291683A external-priority patent/EP1749822B1/de
Priority claimed from US11/197,525 external-priority patent/US20070032499A1/en
Application filed by Hybrigenics Sa filed Critical Hybrigenics Sa
Application granted granted Critical
Publication of ATE501127T1 publication Critical patent/ATE501127T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
AT06808884T 2005-08-05 2006-07-26 Neue cysteinproteasehemmer und ihre therapeutische anwendung ATE501127T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05291683A EP1749822B1 (de) 2005-08-05 2005-08-05 Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
US11/197,525 US20070032499A1 (en) 2005-08-05 2005-08-05 Novel cysteine protease inhibitors and their therapeutic applications
PCT/IB2006/002637 WO2007017758A2 (en) 2005-08-05 2006-07-26 Novel cysteine protease inhibitors and their therapeutic applications

Publications (1)

Publication Number Publication Date
ATE501127T1 true ATE501127T1 (de) 2011-03-15

Family

ID=37507720

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06808884T ATE501127T1 (de) 2005-08-05 2006-07-26 Neue cysteinproteasehemmer und ihre therapeutische anwendung

Country Status (16)

Country Link
US (1) US8648076B2 (de)
EP (1) EP1912954B1 (de)
JP (2) JP5523703B2 (de)
AT (1) ATE501127T1 (de)
AU (1) AU2006277678B2 (de)
CA (1) CA2617725C (de)
DE (1) DE602006020585D1 (de)
DK (1) DK1912954T3 (de)
ES (1) ES2363743T3 (de)
IL (1) IL189286A (de)
NO (1) NO20080661L (de)
NZ (1) NZ565670A (de)
PL (1) PL1912954T3 (de)
RU (1) RU2424234C2 (de)
UA (1) UA96269C2 (de)
WO (1) WO2007017758A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2424234C2 (ru) * 2005-08-05 2011-07-20 Ибриженикс Са Новые ингибиторы цистеиновых протеаз и их терапевтическое применение
MX2009004517A (es) * 2006-10-30 2009-05-13 Hybrigenics Sa Nuevos inhibidores tetraciclicos de las proteasas de cisteina, las composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
EP2824113B1 (de) 2013-07-09 2017-05-03 Samsung Electronics Co., Ltd Biomarker zur auswahl einer person zur anwendung eines anti-c-met-antikörpers
US9567510B2 (en) 2014-09-11 2017-02-14 Halliburton Energy Services, Inc. Cyanamide-based carbon dioxide and/or hydrogen sulfide scavengers and methods of use in subterranean operations
EP3882236B1 (de) 2015-11-10 2023-01-11 Kyushu University National University Corporation Herstellungsverfahren für 2,5-dicyano-3,6-dihalogenopyrazin
WO2021170290A1 (en) * 2020-02-28 2021-09-02 Immunologik Gmbh Inhibitors of human deubiquitinases for the treatment of coronaviral infections

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2152944C1 (ru) * 1993-04-08 2000-07-20 Дзе Дюпон Мерк Фармасьютикал Компани Полициклические соединения, их производные, фармацевтические препараты как усилители и метод лечения нарушения мыслительной деятельности
JP3219339B2 (ja) * 1993-06-15 2001-10-15 株式会社リコー ピラジン化合物及びそれを含有する電子写真感光体
JPH0798508A (ja) * 1993-09-28 1995-04-11 Ricoh Co Ltd 単層型電子写真感光体
JPH07175235A (ja) 1993-12-20 1995-07-14 Ricoh Co Ltd 単層型電子写真用感光体
JP3255525B2 (ja) 1993-12-23 2002-02-12 株式会社リコー ピラジン化合物及びそれを含有する電子写真感光体
JPH07199487A (ja) 1993-12-30 1995-08-04 Ricoh Co Ltd 電子写真用感光体
JPH07199486A (ja) 1993-12-30 1995-08-04 Ricoh Co Ltd 電子写真用感光体
JPH07281460A (ja) 1994-04-14 1995-10-27 Ricoh Co Ltd 潜像転写用電子写真感光体
EP0944582B1 (de) * 1996-12-11 2003-07-02 Abbott GmbH & Co. KG Ketobenzamide als calpain-inhibitoren
JP2000122316A (ja) 1998-10-19 2000-04-28 Ricoh Co Ltd 電子写真感光体
JP2000128885A (ja) 1998-10-19 2000-05-09 Ricoh Co Ltd テトラピラジノポルフィラジン化合物及びその製造方法
JP2001028885A (ja) 1999-07-12 2001-01-30 Sanyo Electric Co Ltd 電源装置
EP1367432A4 (de) 2001-01-30 2008-01-09 Yoshinobu Maeda Verfahren und einrichtung zur optischen steuerung
AU2002305926A1 (en) * 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
PL370766A1 (en) 2001-12-04 2005-05-30 F.Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
JP4272068B2 (ja) 2001-12-26 2009-06-03 日本曹達株式会社 自己組織化単分子膜を形成する電子受容性化合物
US7279478B2 (en) 2002-09-04 2007-10-09 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
RU2424234C2 (ru) * 2005-08-05 2011-07-20 Ибриженикс Са Новые ингибиторы цистеиновых протеаз и их терапевтическое применение

Also Published As

Publication number Publication date
DE602006020585D1 (de) 2011-04-21
IL189286A (en) 2013-08-29
DK1912954T3 (da) 2011-05-23
JP2009503052A (ja) 2009-01-29
UA96269C2 (uk) 2011-10-25
JP5523703B2 (ja) 2014-06-18
RU2424234C2 (ru) 2011-07-20
NZ565670A (en) 2010-01-29
EP1912954B1 (de) 2011-03-09
AU2006277678B2 (en) 2012-04-19
PL1912954T3 (pl) 2011-09-30
WO2007017758A3 (en) 2007-04-19
WO2007017758A2 (en) 2007-02-15
CA2617725C (en) 2012-04-03
US20090215786A1 (en) 2009-08-27
RU2008108501A (ru) 2009-09-10
CA2617725A1 (en) 2007-02-15
AU2006277678A1 (en) 2007-02-15
ES2363743T3 (es) 2011-08-12
NO20080661L (no) 2008-03-04
IL189286A0 (en) 2008-06-05
JP2013166798A (ja) 2013-08-29
US8648076B2 (en) 2014-02-11
EP1912954A2 (de) 2008-04-23

Similar Documents

Publication Publication Date Title
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
EA201070247A1 (ru) Ингибиторы протеасом
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
EA201790678A1 (ru) Бициклические гетероарильные соединения
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
EA200801199A1 (ru) Ингибиторы киназы
EA201000069A1 (ru) Новые гербициды
DE602005010421D1 (de) Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
TW200745122A (en) New compounds I
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
TW200745039A (en) Isotopically substituted pantoprazole
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1912954

Country of ref document: EP